Drug
Trastuzumab Emtansine
Drug Profile
| Therapeutic Class | Antibody-Drug Conjugates (ADCs) |
| Drug Class | — |
| Group | ADC |
| Mechanism of Action | HER2 targeting ADC |
| Half-life | 4 d (popPK 3.94 d) |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing in a HER2-selective manner (DM1 G2/M arrest, ↑DSBs) (Adams et al., Nature Communications, 2016; Cazzamalli et al., Nature Cancer, 2025). The principal theoretical added toxicity is enhanced CNS normal-tissue injury (symptomatic brain radionecrosis) where the maytansinoid payload sensitizes tissue coinciding with intracranial radiation fields.
Data on this page refer exclusively to patients treated with
Trastuzumab Emtansine combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
ADC group page.